西藏药业：预计2026年佐利替尼收益不会对公司产生较大的影响

Core Viewpoint - Xizang Pharmaceutical (600211) has developed Zolertinib, the world's first drug specifically targeting advanced non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases, achieving significant results in clinical trials [1] Group 1 - Zolertinib is the only EGFR tyrosine kinase inhibitor (EGFR-TKI) designed with a substrate for non-blood-brain barrier efflux proteins, demonstrating 100% ability to penetrate the blood-brain barrier [1] - The drug received approval for market launch in November 2024 and was successfully included in the national medical insurance catalog in December 2025, which opens up sales channels for the future [1] - However, due to the time required for market introduction and hospital access for new drugs, it is expected that the revenue from this product will not significantly impact the company in 2026 [1]